You are here

Study: Increased Risk of Kidney Failure, Heart Attack, and Stroke Reported With Aprotinin in Cardiac Surgery

January 26, 2006 -- San Bruno, CA -- Aprotinin (Trasylol), a widely used heart-surgery medication that is standard therapy in many hospitals, has been found to carry increased risk of kidney failure, heart attacks, and strokes as compared with patients taking alternative drugs or no drugs at all. Researchers at the Ischemia Research and Education Foundation in San Bruno, CA, also examined alternatives and found them to be just as effective in limiting blood loss but didn't cause any of the dangerous side effects associated with Trasylol.

Trasylol has been approved since 1993 and it is given to about a quarter of the million people worldwide who undergo bypass surgery each year, the study's author estimates.

To read the study abstract, visit the New England Journal of Medicine's Web site and read the accompany editorial.

Bayer, the manufacturer of Trasylol, has issued a statement, available on the company's Web site.

Sources: New England Journal of Medicine

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs